Abacavir sulfate, Lamivudine and Zidovudine — Competitive Intelligence Brief

Abacavir sulfate, Lamivudine and Zidovudine (Abacavir sulfate, Lamivudine and Zidovudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI) combination. Area: Infectious Disease / Virology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Abacavir sulfate, Lamivudine and Zidovudine (Abacavir sulfate, Lamivudine and Zidovudine) — National Institute of Allergy and Infectious Diseases (NIAID). This combination of three nucleoside reverse transcriptase inhibitors (NRTIs) blocks HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abacavir sulfate, Lamivudine and Zidovudine TARGET	Abacavir sulfate, Lamivudine and Zidovudine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Tenofovir/Emtricitabine	Tenofovir/Emtricitabine	Bristol-Myers Squibb	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
Lamivudine / Abacavir Sulfate	Lamivudine / Abacavir Sulfate	GlaxoSmithKline	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Regimen:TDF+3TC+EFV	Regimen:TDF+3TC+EFV	National Center for AIDS/STD Control and Prevention, China CDC	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
Twice-daily ABC+3TC	Twice-daily ABC+3TC	Medical Research Council	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
AZT+3TC+ABV (Trizivir)	AZT+3TC+ABV (Trizivir)	Fundacion SEIMC-GESIDA	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) combination class)

1. Medical Research Council · 2 drugs in this class
2. Bristol-Myers Squibb · 1 drug in this class
3. Fundacion SEIMC-GESIDA · 1 drug in this class
4. GlaxoSmithKline · 1 drug in this class
5. Janssen Scientific Affairs, LLC · 1 drug in this class
6. Merck Sharp & Dohme LLC · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. Tibotec, Inc · 1 drug in this class
9. University of North Carolina, Chapel Hill · 1 drug in this class
10. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class